nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Carboplatin—breast cancer	0.37	0.636	CbGbCtD
Deferoxamine—XDH—Doxorubicin—breast cancer	0.212	0.364	CbGbCtD
Deferoxamine—XDH—Effects of Nitric Oxide—HBA1—breast cancer	0.00584	0.102	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—APRT—breast cancer	0.00367	0.0641	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—ADSL—breast cancer	0.00299	0.0523	CbGpPWpGaD
Deferoxamine—XDH—Purine catabolism—GPX1—breast cancer	0.00291	0.0508	CbGpPWpGaD
Deferoxamine—XDH—Effects of Nitric Oxide—NOS2—breast cancer	0.00278	0.0486	CbGpPWpGaD
Deferoxamine—XDH—Effects of Nitric Oxide—NOS3—breast cancer	0.00224	0.0391	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—CDA—breast cancer	0.00198	0.0347	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—APRT—breast cancer	0.00184	0.0322	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—NQO1—breast cancer	0.00164	0.0287	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—NME1—breast cancer	0.0015	0.0263	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—UMPS—breast cancer	0.0015	0.0263	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—ADSL—breast cancer	0.0015	0.0263	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—HMOX1—breast cancer	0.00135	0.0236	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—SOD2—breast cancer	0.00127	0.0221	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—GPX1—breast cancer	0.00121	0.0211	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—CYP1A1—breast cancer	0.0012	0.0209	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—GPX2—breast cancer	0.00113	0.0198	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—GPX1—breast cancer	0.00112	0.0195	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—GPX4—breast cancer	0.00112	0.0195	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—DPYD—breast cancer	0.00104	0.0182	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—FOS—breast cancer	0.000893	0.0156	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MTR—breast cancer	0.00088	0.0154	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—HBA1—breast cancer	0.000857	0.015	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PTGS1—breast cancer	0.000784	0.0137	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PLG—breast cancer	0.00062	0.0108	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—TYMS—breast cancer	0.000594	0.0104	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—GPX1—breast cancer	0.000562	0.00982	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD2—breast cancer	0.000535	0.00935	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—GPX1—breast cancer	0.00051	0.00892	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MTHFR—breast cancer	0.000471	0.00823	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SERPINE1—breast cancer	0.000344	0.00601	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ALB—breast cancer	0.000343	0.006	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—IFNG—breast cancer	0.000313	0.00548	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—RELA—breast cancer	0.000309	0.0054	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PTGS2—breast cancer	0.0003	0.00525	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—IL1B—breast cancer	0.00028	0.00488	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SYNJ2—breast cancer	0.000238	0.00415	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NDUFS3—breast cancer	0.000221	0.00386	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CHST9—breast cancer	0.000208	0.00363	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—TNF—breast cancer	0.000203	0.00354	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—COX11—breast cancer	0.000197	0.00344	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CDA—breast cancer	0.00018	0.00315	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SHMT1—breast cancer	0.00018	0.00315	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SLC2A5—breast cancer	0.000173	0.00303	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SLCO1B1—breast cancer	0.000173	0.00303	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—APRT—breast cancer	0.000168	0.00293	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—IL6—breast cancer	0.000164	0.00286	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ANGPTL4—breast cancer	0.000158	0.00275	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ESRRA—breast cancer	0.000158	0.00275	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GPI—breast cancer	0.000149	0.00261	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HADHB—breast cancer	0.000149	0.00261	CbGpPWpGaD
Deferoxamine—Abdominal pain—Mitoxantrone—breast cancer	0.000146	0.000406	CcSEcCtD
Deferoxamine—Muscle spasms—Capecitabine—breast cancer	0.000146	0.000405	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—breast cancer	0.000145	0.000401	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—breast cancer	0.000145	0.000401	CcSEcCtD
Deferoxamine—Vision blurred—Capecitabine—breast cancer	0.000143	0.000397	CcSEcCtD
Deferoxamine—Vomiting—Vinorelbine—breast cancer	0.000143	0.000396	CcSEcCtD
Deferoxamine—Body temperature increased—Gemcitabine—breast cancer	0.000143	0.000396	CcSEcCtD
Deferoxamine—XDH—Metabolism—ALDH7A1—breast cancer	0.000142	0.00249	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ALDH1A1—breast cancer	0.000142	0.00249	CbGpPWpGaD
Deferoxamine—Renal failure—Methotrexate—breast cancer	0.000142	0.000395	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—breast cancer	0.000142	0.000394	CcSEcCtD
Deferoxamine—Dizziness—Thiotepa—breast cancer	0.000142	0.000394	CcSEcCtD
Deferoxamine—Hypotension—Paclitaxel—breast cancer	0.000141	0.000392	CcSEcCtD
Deferoxamine—Urticaria—Fluorouracil—breast cancer	0.000141	0.000391	CcSEcCtD
Deferoxamine—Headache—Vinorelbine—breast cancer	0.000141	0.00039	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—breast cancer	0.00014	0.00039	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—breast cancer	0.00014	0.00039	CcSEcCtD
Deferoxamine—Body temperature increased—Fluorouracil—breast cancer	0.00014	0.000389	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—breast cancer	0.000139	0.000386	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.000138	0.000382	CcSEcCtD
Deferoxamine—XDH—Metabolism—PHGDH—breast cancer	0.000137	0.00239	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—FHL2—breast cancer	0.000137	0.00239	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NME1—breast cancer	0.000137	0.00239	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ADSL—breast cancer	0.000137	0.00239	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—UMPS—breast cancer	0.000137	0.00239	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Mitoxantrone—breast cancer	0.000136	0.000379	CcSEcCtD
Deferoxamine—Hypersensitivity—Irinotecan—breast cancer	0.000136	0.000379	CcSEcCtD
Deferoxamine—Vomiting—Thiotepa—breast cancer	0.000136	0.000378	CcSEcCtD
Deferoxamine—Leukopenia—Capecitabine—breast cancer	0.000136	0.000377	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—breast cancer	0.000136	0.000377	CcSEcCtD
Deferoxamine—Paraesthesia—Paclitaxel—breast cancer	0.000136	0.000376	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—breast cancer	0.000135	0.000376	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—breast cancer	0.000135	0.000376	CcSEcCtD
Deferoxamine—Dyspnoea—Paclitaxel—breast cancer	0.000135	0.000374	CcSEcCtD
Deferoxamine—Headache—Thiotepa—breast cancer	0.000134	0.000373	CcSEcCtD
Deferoxamine—XDH—Metabolism—HPSE—breast cancer	0.000134	0.00234	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—BRIP1—breast cancer	0.000134	0.00234	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—LDHB—breast cancer	0.000134	0.00234	CbGpPWpGaD
Deferoxamine—Myalgia—Docetaxel—breast cancer	0.000133	0.000371	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—breast cancer	0.000133	0.000371	CcSEcCtD
Deferoxamine—Nausea—Vinorelbine—breast cancer	0.000133	0.00037	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—breast cancer	0.000133	0.000369	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—breast cancer	0.000133	0.000368	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000133	0.000368	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—breast cancer	0.000131	0.000365	CcSEcCtD
Deferoxamine—Hypersensitivity—Fluorouracil—breast cancer	0.000131	0.000363	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.00013	0.000362	CcSEcCtD
Deferoxamine—Myalgia—Capecitabine—breast cancer	0.000129	0.000359	CcSEcCtD
Deferoxamine—Arthralgia—Capecitabine—breast cancer	0.000129	0.000359	CcSEcCtD
Deferoxamine—Pain—Paclitaxel—breast cancer	0.000129	0.000358	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000128	0.000356	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—breast cancer	0.000128	0.000356	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—breast cancer	0.000128	0.000355	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—breast cancer	0.000128	0.000355	CcSEcCtD
Deferoxamine—Pruritus—Gemcitabine—breast cancer	0.000128	0.000354	CcSEcCtD
Deferoxamine—Nausea—Thiotepa—breast cancer	0.000127	0.000353	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—breast cancer	0.000127	0.000353	CcSEcCtD
Deferoxamine—Infection—Docetaxel—breast cancer	0.000127	0.000353	CcSEcCtD
Deferoxamine—XDH—Metabolism—ABCC1—breast cancer	0.000127	0.00222	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTA3—breast cancer	0.000127	0.00222	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HMMR—breast cancer	0.000127	0.00222	CbGpPWpGaD
Deferoxamine—Diarrhoea—Irinotecan—breast cancer	0.000127	0.000352	CcSEcCtD
Deferoxamine—Diarrhoea—Mitoxantrone—breast cancer	0.000127	0.000352	CcSEcCtD
Deferoxamine—Shock—Docetaxel—breast cancer	0.000126	0.00035	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—breast cancer	0.000125	0.000348	CcSEcCtD
Deferoxamine—Pruritus—Fluorouracil—breast cancer	0.000125	0.000348	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—breast cancer	0.000125	0.000348	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—breast cancer	0.000125	0.000348	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—breast cancer	0.000125	0.000348	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—breast cancer	0.000125	0.000347	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—breast cancer	0.000125	0.000347	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—breast cancer	0.000124	0.000345	CcSEcCtD
Deferoxamine—Oedema—Capecitabine—breast cancer	0.000124	0.000344	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—breast cancer	0.000124	0.000343	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Paclitaxel—breast cancer	0.000123	0.000343	CcSEcCtD
Deferoxamine—Diarrhoea—Gemcitabine—breast cancer	0.000123	0.000343	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—breast cancer	0.000123	0.000342	CcSEcCtD
Deferoxamine—Infection—Capecitabine—breast cancer	0.000123	0.000342	CcSEcCtD
Deferoxamine—XDH—Metabolism—PPARGC1B—breast cancer	0.000123	0.00215	CbGpPWpGaD
Deferoxamine—Neuropathy peripheral—Doxorubicin—breast cancer	0.000123	0.000341	CcSEcCtD
Deferoxamine—Dizziness—Irinotecan—breast cancer	0.000122	0.00034	CcSEcCtD
Deferoxamine—Shock—Capecitabine—breast cancer	0.000122	0.000338	CcSEcCtD
Deferoxamine—Nervous system disorder—Capecitabine—breast cancer	0.000121	0.000337	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—breast cancer	0.000121	0.000337	CcSEcCtD
Deferoxamine—Diarrhoea—Fluorouracil—breast cancer	0.000121	0.000337	CcSEcCtD
Deferoxamine—Thrombocytopenia—Capecitabine—breast cancer	0.000121	0.000337	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—breast cancer	0.000121	0.000336	CcSEcCtD
Deferoxamine—Tachycardia—Capecitabine—breast cancer	0.000121	0.000336	CcSEcCtD
Deferoxamine—Skin disorder—Capecitabine—breast cancer	0.00012	0.000334	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—breast cancer	0.00012	0.000333	CcSEcCtD
Deferoxamine—Urticaria—Paclitaxel—breast cancer	0.00012	0.000333	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—breast cancer	0.00012	0.000332	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—breast cancer	0.000119	0.000331	CcSEcCtD
Deferoxamine—Body temperature increased—Paclitaxel—breast cancer	0.000119	0.000331	CcSEcCtD
Deferoxamine—Abdominal pain—Paclitaxel—breast cancer	0.000119	0.000331	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—breast cancer	0.000119	0.000331	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—breast cancer	0.000118	0.000327	CcSEcCtD
Deferoxamine—Vomiting—Mitoxantrone—breast cancer	0.000118	0.000327	CcSEcCtD
Deferoxamine—Vomiting—Irinotecan—breast cancer	0.000118	0.000327	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—breast cancer	0.000117	0.000326	CcSEcCtD
Deferoxamine—Dizziness—Fluorouracil—breast cancer	0.000117	0.000326	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—breast cancer	0.000117	0.000325	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—breast cancer	0.000117	0.000325	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000117	0.000324	CcSEcCtD
Deferoxamine—XDH—Metabolism—CA9—breast cancer	0.000116	0.00203	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTA4—breast cancer	0.000116	0.00203	CbGpPWpGaD
Deferoxamine—Headache—Irinotecan—breast cancer	0.000116	0.000322	CcSEcCtD
Deferoxamine—Headache—Mitoxantrone—breast cancer	0.000116	0.000322	CcSEcCtD
Deferoxamine—Hypotension—Capecitabine—breast cancer	0.000116	0.000321	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—breast cancer	0.000115	0.000319	CcSEcCtD
Deferoxamine—Vomiting—Gemcitabine—breast cancer	0.000115	0.000318	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—breast cancer	0.000114	0.000318	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—breast cancer	0.000114	0.000317	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—breast cancer	0.000114	0.000315	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—breast cancer	0.000113	0.000314	CcSEcCtD
Deferoxamine—XDH—Metabolism—GPX2—breast cancer	0.000113	0.00198	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTA2—breast cancer	0.000113	0.00198	CbGpPWpGaD
Deferoxamine—Erythema—Methotrexate—breast cancer	0.000113	0.000314	CcSEcCtD
Deferoxamine—Headache—Gemcitabine—breast cancer	0.000113	0.000314	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000113	0.000313	CcSEcCtD
Deferoxamine—Vomiting—Fluorouracil—breast cancer	0.000113	0.000313	CcSEcCtD
Deferoxamine—XDH—Metabolism—SULT1A1—breast cancer	0.000112	0.00195	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GPX4—breast cancer	0.000112	0.00195	CbGpPWpGaD
Deferoxamine—Paraesthesia—Capecitabine—breast cancer	0.000111	0.000309	CcSEcCtD
Deferoxamine—Hypersensitivity—Paclitaxel—breast cancer	0.000111	0.000309	CcSEcCtD
Deferoxamine—Headache—Fluorouracil—breast cancer	0.000111	0.000308	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—breast cancer	0.000111	0.000308	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—breast cancer	0.00011	0.000307	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—breast cancer	0.00011	0.000307	CcSEcCtD
Deferoxamine—Dyspnoea—Capecitabine—breast cancer	0.00011	0.000307	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—breast cancer	0.00011	0.000306	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—breast cancer	0.00011	0.000306	CcSEcCtD
Deferoxamine—Nausea—Mitoxantrone—breast cancer	0.00011	0.000305	CcSEcCtD
Deferoxamine—Nausea—Irinotecan—breast cancer	0.00011	0.000305	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—breast cancer	0.00011	0.000305	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—breast cancer	0.000109	0.000304	CcSEcCtD
Deferoxamine—Pain—Docetaxel—breast cancer	0.000109	0.000304	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA1—breast cancer	0.000109	0.00191	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—IDH1—breast cancer	0.000109	0.00191	CbGpPWpGaD
Deferoxamine—Arrhythmia—Epirubicin—breast cancer	0.000108	0.000301	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—breast cancer	0.000108	0.000301	CcSEcCtD
Deferoxamine—XDH—Metabolism—NAT2—breast cancer	0.000108	0.00189	CbGpPWpGaD
Deferoxamine—Nausea—Gemcitabine—breast cancer	0.000107	0.000297	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000107	0.000297	CcSEcCtD
Deferoxamine—Pruritus—Paclitaxel—breast cancer	0.000107	0.000297	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—breast cancer	0.000106	0.000296	CcSEcCtD
Deferoxamine—Pain—Capecitabine—breast cancer	0.000106	0.000294	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—breast cancer	0.000106	0.000294	CcSEcCtD
Deferoxamine—Nausea—Fluorouracil—breast cancer	0.000105	0.000292	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—breast cancer	0.000105	0.000292	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—breast cancer	0.000105	0.000291	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—breast cancer	0.000105	0.000291	CcSEcCtD
Deferoxamine—Diarrhoea—Paclitaxel—breast cancer	0.000103	0.000287	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—breast cancer	0.000102	0.000283	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—breast cancer	0.000102	0.000282	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—breast cancer	0.000102	0.000282	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Capecitabine—breast cancer	0.000101	0.000281	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—breast cancer	0.000101	0.000281	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—breast cancer	0.000101	0.000281	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—breast cancer	0.000101	0.000281	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—breast cancer	0.000101	0.000281	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—breast cancer	0.0001	0.000279	CcSEcCtD
Deferoxamine—Dizziness—Paclitaxel—breast cancer	9.98e-05	0.000277	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—breast cancer	9.96e-05	0.000277	CcSEcCtD
Deferoxamine—Urticaria—Capecitabine—breast cancer	9.84e-05	0.000273	CcSEcCtD
Deferoxamine—Body temperature increased—Capecitabine—breast cancer	9.79e-05	0.000272	CcSEcCtD
Deferoxamine—Abdominal pain—Capecitabine—breast cancer	9.79e-05	0.000272	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—breast cancer	9.79e-05	0.000272	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—breast cancer	9.78e-05	0.000272	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—breast cancer	9.62e-05	0.000267	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—breast cancer	9.62e-05	0.000267	CcSEcCtD
Deferoxamine—Vomiting—Paclitaxel—breast cancer	9.6e-05	0.000267	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	9.55e-05	0.000265	CcSEcCtD
Deferoxamine—XDH—Metabolism—DPYD—breast cancer	9.47e-05	0.00165	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—MED12—breast cancer	9.47e-05	0.00165	CbGpPWpGaD
Deferoxamine—Leukopenia—Epirubicin—breast cancer	9.46e-05	0.000263	CcSEcCtD
Deferoxamine—Headache—Paclitaxel—breast cancer	9.46e-05	0.000263	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—breast cancer	9.43e-05	0.000262	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—breast cancer	9.41e-05	0.000261	CcSEcCtD
Deferoxamine—XDH—Metabolism—ALDOA—breast cancer	9.32e-05	0.00163	CbGpPWpGaD
Deferoxamine—Anaphylactic shock—Methotrexate—breast cancer	9.22e-05	0.000256	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—breast cancer	9.22e-05	0.000256	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—breast cancer	9.16e-05	0.000254	CcSEcCtD
Deferoxamine—Infection—Methotrexate—breast cancer	9.16e-05	0.000254	CcSEcCtD
Deferoxamine—Hypersensitivity—Capecitabine—breast cancer	9.13e-05	0.000253	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—breast cancer	9.05e-05	0.000251	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOA3—breast cancer	9.05e-05	0.00158	CbGpPWpGaD
Deferoxamine—Nervous system disorder—Methotrexate—breast cancer	9.04e-05	0.000251	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—breast cancer	9.03e-05	0.000251	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—breast cancer	9e-05	0.00025	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—breast cancer	9e-05	0.00025	CcSEcCtD
Deferoxamine—XDH—Metabolism—SLC2A2—breast cancer	8.98e-05	0.00157	CbGpPWpGaD
Deferoxamine—Nausea—Paclitaxel—breast cancer	8.96e-05	0.000249	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—breast cancer	8.96e-05	0.000249	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	8.94e-05	0.000248	CcSEcCtD
Deferoxamine—XDH—Metabolism—MTR—breast cancer	8.8e-05	0.00154	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CPT1A—breast cancer	8.8e-05	0.00154	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ABCG2—breast cancer	8.8e-05	0.00154	CbGpPWpGaD
Deferoxamine—Pruritus—Capecitabine—breast cancer	8.76e-05	0.000243	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—breast cancer	8.76e-05	0.000243	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—breast cancer	8.75e-05	0.000243	CcSEcCtD
Deferoxamine—XDH—Metabolism—HPGDS—breast cancer	8.63e-05	0.00151	CbGpPWpGaD
Deferoxamine—Oedema—Epirubicin—breast cancer	8.63e-05	0.00024	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—breast cancer	8.63e-05	0.00024	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—breast cancer	8.62e-05	0.000239	CcSEcCtD
Deferoxamine—XDH—Metabolism—HBA1—breast cancer	8.58e-05	0.0015	CbGpPWpGaD
Deferoxamine—Infection—Epirubicin—breast cancer	8.57e-05	0.000238	CcSEcCtD
Deferoxamine—Shock—Epirubicin—breast cancer	8.49e-05	0.000236	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—breast cancer	8.48e-05	0.000235	CcSEcCtD
Deferoxamine—Diarrhoea—Capecitabine—breast cancer	8.47e-05	0.000235	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—breast cancer	8.46e-05	0.000235	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—breast cancer	8.46e-05	0.000235	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—breast cancer	8.45e-05	0.000235	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—breast cancer	8.42e-05	0.000234	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—breast cancer	8.4e-05	0.000233	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—breast cancer	8.38e-05	0.000233	CcSEcCtD
Deferoxamine—XDH—Metabolism—ACHE—breast cancer	8.37e-05	0.00146	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTT1—breast cancer	8.37e-05	0.00146	CbGpPWpGaD
Deferoxamine—Arthralgia—Doxorubicin—breast cancer	8.33e-05	0.000231	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—breast cancer	8.33e-05	0.000231	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—breast cancer	8.28e-05	0.00023	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	8.27e-05	0.00023	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—breast cancer	8.22e-05	0.000228	CcSEcCtD
Deferoxamine—Dizziness—Capecitabine—breast cancer	8.19e-05	0.000227	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—breast cancer	8.13e-05	0.000226	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—breast cancer	8.06e-05	0.000224	CcSEcCtD
Deferoxamine—Headache—Docetaxel—breast cancer	8.01e-05	0.000223	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—breast cancer	7.98e-05	0.000222	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—breast cancer	7.98e-05	0.000222	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—breast cancer	7.96e-05	0.000221	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—breast cancer	7.93e-05	0.00022	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP17A1—breast cancer	7.92e-05	0.00138	CbGpPWpGaD
Deferoxamine—Pain—Methotrexate—breast cancer	7.88e-05	0.000219	CcSEcCtD
Deferoxamine—Vomiting—Capecitabine—breast cancer	7.88e-05	0.000219	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—breast cancer	7.86e-05	0.000218	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—breast cancer	7.85e-05	0.000218	CcSEcCtD
Deferoxamine—XDH—Metabolism—PTGS1—breast cancer	7.84e-05	0.00137	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ENO1—breast cancer	7.84e-05	0.00137	CbGpPWpGaD
Deferoxamine—Nervous system disorder—Doxorubicin—breast cancer	7.83e-05	0.000217	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—breast cancer	7.82e-05	0.000217	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—breast cancer	7.79e-05	0.000216	CcSEcCtD
Deferoxamine—Headache—Capecitabine—breast cancer	7.76e-05	0.000215	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—breast cancer	7.75e-05	0.000215	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—breast cancer	7.75e-05	0.000215	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP2D6—breast cancer	7.69e-05	0.00134	CbGpPWpGaD
Deferoxamine—Dyspnoea—Epirubicin—breast cancer	7.69e-05	0.000214	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—breast cancer	7.6e-05	0.000211	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOA2—breast cancer	7.55e-05	0.00132	CbGpPWpGaD
Deferoxamine—Gastrointestinal pain—Methotrexate—breast cancer	7.54e-05	0.000209	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—breast cancer	7.46e-05	0.000207	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—breast cancer	7.45e-05	0.000207	CcSEcCtD
Deferoxamine—Pain—Epirubicin—breast cancer	7.38e-05	0.000205	CcSEcCtD
Deferoxamine—Nausea—Capecitabine—breast cancer	7.36e-05	0.000204	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—breast cancer	7.32e-05	0.000203	CcSEcCtD
Deferoxamine—XDH—Metabolism—FASN—breast cancer	7.32e-05	0.00128	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—BCHE—breast cancer	7.29e-05	0.00127	CbGpPWpGaD
Deferoxamine—Abdominal pain—Methotrexate—breast cancer	7.29e-05	0.000202	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—breast cancer	7.29e-05	0.000202	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.27e-05	0.000202	CcSEcCtD
Deferoxamine—XDH—Metabolism—SLC5A5—breast cancer	7.2e-05	0.00126	CbGpPWpGaD
Deferoxamine—Paraesthesia—Doxorubicin—breast cancer	7.17e-05	0.000199	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—breast cancer	7.12e-05	0.000198	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—breast cancer	7.06e-05	0.000196	CcSEcCtD
Deferoxamine—XDH—Metabolism—NQO1—breast cancer	6.96e-05	0.00122	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SLC2A1—breast cancer	6.96e-05	0.00122	CbGpPWpGaD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—breast cancer	6.89e-05	0.000191	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—breast cancer	6.85e-05	0.00019	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—breast cancer	6.83e-05	0.00019	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—breast cancer	6.82e-05	0.000189	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—breast cancer	6.82e-05	0.000189	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—breast cancer	6.79e-05	0.000189	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP3A4—breast cancer	6.78e-05	0.00119	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP1B1—breast cancer	6.67e-05	0.00117	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HSP90AA1—breast cancer	6.54e-05	0.00114	CbGpPWpGaD
Deferoxamine—Gastrointestinal pain—Doxorubicin—breast cancer	6.53e-05	0.000181	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—breast cancer	6.52e-05	0.000181	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOA1—breast cancer	6.36e-05	0.00111	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Epirubicin—breast cancer	6.36e-05	0.000177	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—breast cancer	6.34e-05	0.000176	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—breast cancer	6.31e-05	0.000175	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—breast cancer	6.31e-05	0.000175	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—breast cancer	6.31e-05	0.000175	CcSEcCtD
Deferoxamine—XDH—Metabolism—STK11—breast cancer	6.27e-05	0.0011	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP19A1—breast cancer	6.27e-05	0.0011	CbGpPWpGaD
Deferoxamine—Pruritus—Epirubicin—breast cancer	6.1e-05	0.00017	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—breast cancer	6.1e-05	0.000169	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—breast cancer	5.9e-05	0.000164	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—breast cancer	5.88e-05	0.000163	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—breast cancer	5.86e-05	0.000163	CcSEcCtD
Deferoxamine—XDH—Metabolism—COMT—breast cancer	5.83e-05	0.00102	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTP1—breast cancer	5.8e-05	0.00101	CbGpPWpGaD
Deferoxamine—Headache—Methotrexate—breast cancer	5.78e-05	0.00016	CcSEcCtD
Deferoxamine—XDH—Metabolism—HMOX1—breast cancer	5.72e-05	0.001	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ITPR1—breast cancer	5.71e-05	0.000997	CbGpPWpGaD
Deferoxamine—Dizziness—Epirubicin—breast cancer	5.71e-05	0.000158	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—breast cancer	5.65e-05	0.000157	CcSEcCtD
Deferoxamine—XDH—Metabolism—ABCB1—breast cancer	5.49e-05	0.00096	CbGpPWpGaD
Deferoxamine—Vomiting—Epirubicin—breast cancer	5.49e-05	0.000152	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—breast cancer	5.48e-05	0.000152	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—breast cancer	5.46e-05	0.000152	CcSEcCtD
Deferoxamine—Headache—Epirubicin—breast cancer	5.41e-05	0.00015	CcSEcCtD
Deferoxamine—XDH—Metabolism—TYMS—breast cancer	5.39e-05	0.000942	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NCOR1—breast cancer	5.33e-05	0.000932	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTM1—breast cancer	5.33e-05	0.000932	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PLA2G4A—breast cancer	5.33e-05	0.000932	CbGpPWpGaD
Deferoxamine—Dizziness—Doxorubicin—breast cancer	5.28e-05	0.000147	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—breast cancer	5.13e-05	0.000142	CcSEcCtD
Deferoxamine—XDH—Metabolism—GPX1—breast cancer	5.11e-05	0.000892	CbGpPWpGaD
Deferoxamine—Vomiting—Doxorubicin—breast cancer	5.08e-05	0.000141	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP1A1—breast cancer	5.06e-05	0.000883	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ERCC2—breast cancer	5.01e-05	0.000876	CbGpPWpGaD
Deferoxamine—Headache—Doxorubicin—breast cancer	5e-05	0.000139	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—breast cancer	4.74e-05	0.000132	CcSEcCtD
Deferoxamine—XDH—Metabolism—MTHFR—breast cancer	4.71e-05	0.000823	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CAV1—breast cancer	4.35e-05	0.000759	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CG—breast cancer	3.96e-05	0.000692	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CD—breast cancer	3.48e-05	0.000608	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ALB—breast cancer	3.44e-05	0.0006	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NOS3—breast cancer	3.29e-05	0.000574	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CB—breast cancer	3.03e-05	0.00053	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTGS2—breast cancer	3.01e-05	0.000525	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTEN—breast cancer	2.62e-05	0.000458	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CA—breast cancer	1.85e-05	0.000323	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AKT1—breast cancer	1.51e-05	0.000264	CbGpPWpGaD
